title: [Update on current care guidelines. Celiac disease].
authors.forename: Pekka
authors.initials: P
authors.lastname: Collin
authors.forename: Risto
authors.initials: R
authors.lastname: Julkunen
authors.forename: Juhani
authors.initials: J
authors.lastname: Lehtola
authors.forename: Katri
authors.initials: K
authors.lastname: Kaukinen
authors.forename: Markku
authors.initials: M
authors.lastname: Mäki
authors.forename: Martin
authors.initials: M
authors.lastname: Rasmussen
authors.forename: Timo
authors.initials: T
authors.lastname: Reunala
authors.forename: Erkki
authors.initials: E
authors.lastname: Savilahti
authors.forename: Matti
authors.initials: M
authors.lastname: Uusitupa
authors.forename: Matti
authors.initials: M
authors.lastname: Vuoristo
authors.forename: Alpo
authors.initials: A
authors.lastname: Vuorio
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D002446:Celiac Disease / Q000178:diet therapy* / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology; D005260:Female; D005387:Finland / Q000453:epidemiology; D005983:Glutens / Q000378:metabolism*; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D015994:Incidence; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D011503:Transglutaminases / Q000378:metabolism
chemical_list: D000888:Antibodies, Anti-Idiotypic; D007070:Immunoglobulin A; D005983:Glutens; D011503:Transglutaminases